REFRACTORY ACUTE MYELOID LEUKEMIA
Clinical trials for REFRACTORY ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested for tough blood cancers in older adults
Disease control TerminatedThis study tested how well two chemotherapy drugs, venetoclax and decitabine, work together to control aggressive blood cancers. It was for older adults newly diagnosed with acute myeloid leukemia (AML) or people whose AML or high-risk myelodysplastic syndrome (MDS) had returned …
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
Scientists test new combo against tough blood cancers
Disease control TerminatedThis early-stage study tested a combination of two chemotherapy drugs, pevonedistat and belinostat, in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had returned or stopped responding to other treatments. The main goal was to find the highest dos…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Scientists test new combo against tough blood cancers
Disease control TerminatedThis early-stage study tested a combination of two drugs, AZD1775 and belinostat, for patients with advanced blood cancers like acute myeloid leukemia (AML) that have returned or not responded to prior treatments. The main goal was to find the safest and most effective dose of th…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
Targeted drug duo tested for tough blood cancers
Disease control TerminatedThis study tested a combination of two drugs, omacetaxine and venetoclax, for adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or stopped responding to treatment, and who have a specific genetic change called RUNX1. The goal was to find the safest,…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC